Plus   Neg

Pfizer, IDEAYA To Evaluate Clinical Combination Of IDE196 & Binimetinib

IDEAYA Biosciences, Inc. (IDYA) has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) for a clinical combination study of IDE196, and binimetinib, in GNAQ or GNA11 hotspot mutated solid tumors. IDEAYA will sponsor the study. Pfizer will supply binimetinib for the study. The trial is expected to begin in mid-2020.

"The prevalence of GNAQ or GNA11 hotspot mutations in Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, and other solid tumors represents approximately 6,000 patients in the U.S. and the five major European countries, and there are no approved targeted therapies for MUM or GNAQ/GNA11 hotspot mutation solid tumors," said Yujiro Hata, CEO, IDEAYA Biosciences.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury. Integrated payments firm American Express Co. (AXP) reported Friday that net income for the third quarter declined to $1.1 billion or $1.30 per share from $1.8 billion or $2.08 per share in the prior-year quarter. Consolidated total revenues, net of interest expense, also decreased 20 percent to $8.8... The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices.
Follow RTT